USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary - Cancer rates are rising everywhere ...

The update strengthens IBTROZI's position as a next-generation treatment in a rare, aggressive lung cancer that often spreads ...

IBTROZI is now positioned as the primary competitor to Nuvalent’s zidesamtinib in the ROS1+ NSCLC treatment landscape. The drug’s approval in a line-agnostic setting and its approximately two-year ...

Nuvation Bio Inc. (NYSE:NUVB) has recently transitioned from a clinical-stage to a commercial-stage biotechnology company with the FDA approval of its flagship drug IBTROZI (taletrectinib) for the ...

Analyses suggest squamous and nonsquamous tumors differ in immunobiology and may respond differently to the addition of LAG-3 inhibitors to PD-1–based therapy.